Suleiman Massarweh

4.6k total citations · 1 hit paper
46 papers, 3.5k citations indexed

About

Suleiman Massarweh is a scholar working on Oncology, Genetics and Cancer Research. According to data from OpenAlex, Suleiman Massarweh has authored 46 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 20 papers in Genetics and 16 papers in Cancer Research. Recurrent topics in Suleiman Massarweh's work include HER2/EGFR in Cancer Research (22 papers), Estrogen and related hormone effects (17 papers) and Breast Cancer Treatment Studies (16 papers). Suleiman Massarweh is often cited by papers focused on HER2/EGFR in Cancer Research (22 papers), Estrogen and related hormone effects (17 papers) and Breast Cancer Treatment Studies (16 papers). Suleiman Massarweh collaborates with scholars based in United States, Switzerland and Canada. Suleiman Massarweh's co-authors include Rachel Schiff, C. Kent Osborne, Jiang Shou, Helen A. Weiss, C. K. Osborne, A. E. Wakeling, Jianzhong Shou, Simak Ali, Lavina Bharwani and Mothaffar F. Rimawi and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Suleiman Massarweh

45 papers receiving 3.5k citations

Hit Papers

1 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer

2004 918 citations Suleiman Massarweh, A. E. Wakeling et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suleiman Massarweh United States	22	2.1k	1.7k	1.5k	877	694	46	3.5k
Lesley‐Ann Martin United Kingdom	33	1.9k 0.9×	1.8k 1.1×	1.2k 0.8×	1.3k 1.5×	1.2k 1.7×	80	3.9k
Jiang Shou United States	15	1.3k 0.6×	1.4k 0.8×	947 0.6×	524 0.6×	352 0.5×	20	2.4k
Charles Morris United Kingdom	12	1.8k 0.8×	695 0.4×	1.1k 0.7×	527 0.6×	1.2k 1.7×	21	2.7k
Dorraya El‐Ashry United States	31	1.7k 0.8×	1.7k 1.0×	789 0.5×	972 1.1×	275 0.4×	52	3.1k
Syed K. Mohsin United States	33	2.4k 1.1×	2.0k 1.1×	1.2k 0.8×	1.9k 2.2×	540 0.8×	43	4.5k
Henk Portengen Netherlands	29	1.5k 0.7×	1.5k 0.9×	808 0.5×	1.2k 1.3×	305 0.4×	40	3.1k
Susan M. Edgerton United States	34	3.2k 1.5×	2.8k 1.6×	614 0.4×	1.8k 2.1×	698 1.0×	62	5.2k
Björn Erikstein Norway	24	1.3k 0.6×	859 0.5×	968 0.6×	702 0.8×	483 0.7×	47	2.7k
Kaija Holli Finland	26	1.7k 0.8×	1.1k 0.6×	1.3k 0.9×	1.3k 1.4×	430 0.6×	54	3.3k
Hiroyoshi Doihara Japan	29	1.4k 0.7×	1.4k 0.8×	332 0.2×	710 0.8×	513 0.7×	161	3.1k

Countries citing papers authored by Suleiman Massarweh

Since Specialization

Citations

This map shows the geographic impact of Suleiman Massarweh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suleiman Massarweh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suleiman Massarweh more than expected).

Fields of papers citing papers by Suleiman Massarweh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suleiman Massarweh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suleiman Massarweh. The network helps show where Suleiman Massarweh may publish in the future.

Co-authorship network of co-authors of Suleiman Massarweh

This figure shows the co-authorship network connecting the top 25 collaborators of Suleiman Massarweh. A scholar is included among the top collaborators of Suleiman Massarweh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suleiman Massarweh. Suleiman Massarweh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Massarweh, Suleiman, et al.. (2018). Molecular Characterization and Mortality From Breast Cancer in Men. Journal of Clinical Oncology. 36(14). 1396–1404. 54 indexed citations

Williams, Michelle M., Linus Lee, Thomas A. Werfel, et al.. (2018). Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death and Disease. 9(2). 21–21. 19 indexed citations

Malorni, Luca, Mario Giuliano, Ilenia Migliaccio, et al.. (2016). Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. Molecular Cancer Research. 14(5). 470–481. 31 indexed citations

Mancuso, Michael R. & Suleiman Massarweh. (2016). Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer. Current Problems in Cancer. 40(2-4). 95–105. 21 indexed citations

Massarweh, Suleiman, et al.. (2016). Special considerations in the evaluation and management of breast cancer in men11This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.. Current Problems in Cancer. 40(2-4). 163–171. 6 indexed citations

Massarweh, Suleiman, et al.. (2013). A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Research and Treatment. 143(2). 325–332. 48 indexed citations

Chen, Albert C., Ilenia Migliaccio, Mothaffar F. Rimawi, et al.. (2012). Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies. Breast Cancer Research and Treatment. 134(2). 583–593. 28 indexed citations

Elledge, Richard, et al.. (2012). Pathologic Changes in Breast Cancer After Anti-Estrogen Therapy. The Breast Journal. 18(4). 362–366. 11 indexed citations

Chen, Li, Edward H. Romond, Saurin Chokshi, et al.. (2012). A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Research and Treatment. 136(2). 565–572. 13 indexed citations

10.

Massarweh, Suleiman, Jian Huang, K. Sexton, et al.. (2011). A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. 129(3). 819–827. 27 indexed citations

11.

Rimawi, Mothaffar F., Lisa Wiechmann, Yen-Chao Wang, et al.. (2010). Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts. Clinical Cancer Research. 17(6). 1351–1361. 66 indexed citations

12.

Massarweh, Suleiman, C. Kent Osborne, Chad J. Creighton, et al.. (2008). Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research. 68(3). 826–833. 375 indexed citations

13.

Creighton, Chad J., Suleiman Massarweh, Shixia Huang, et al.. (2008). Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research. 68(18). 7493–7501. 101 indexed citations

14.

Sughayer, Maher A., et al.. (2006). Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan. Pathology & Oncology Research. 12(2). 83–86. 33 indexed citations

15.

Massarweh, Suleiman & Rachel Schiff. (2006). Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk. Endocrine Related Cancer. 13(Supplement_1). S15–S24. 127 indexed citations

16.

Schiff, Rachel, Suleiman Massarweh, Jiang Shou, et al.. (2005). Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Cancer Chemotherapy and Pharmacology. 56(S1). 10–20. 119 indexed citations

17.

Massarweh, Suleiman, et al.. (2004). Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression. Journal of Clinical Oncology. 22(14_suppl). 541–541. 1 indexed citations

18.

Schiff, Rachel, Suleiman Massarweh, Jiang Shou, & C. Kent Osborne. (2003). Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.. PubMed. 9(1 Pt 2). 447S–54S. 250 indexed citations

19.

Massarweh, Suleiman, et al.. (2003). Small-Cell Cancers, and an Unusual Reaction to Chemotherapy. Journal of Clinical Oncology. 21(12). 2439–2440. 1 indexed citations

20.

Massarweh, Suleiman, Mark M. Udden, Imran Shahab, et al.. (2003). HIV‐Related Hodgkin's disease with central nervous system involvement and association with Epstein‐Barr virus. American Journal of Hematology. 72(3). 216–219. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact